The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases (Q33541425)

27 July 2017

1 reference

title

The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases (English)

1 reference

27 July 2017

1 reference

Bach JF

1

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

Transplantation Proceedings

27 July 2017

published in

1 reference

27 July 2017

volume

31

1 reference

27 July 2017

issue

1-2A

1 reference

27 July 2017

page(s)

16S-18S

1 reference

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Effects of cyclosporine in severe systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Anti-CD4 monoclonal antibody therapy in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Trial of cyclosporin in corticosteroid-dependent chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

The risk of neoplasms in patients treated with cyclosporine A.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2898%2902075-2

7 January 2021

10.1016/S0041-1345(98)02075-2

Identifiers

DOI

1 reference

27 July 2017

1 reference